Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/eye.2015.87 http://scihub22266oqcxt.onion/10.1038/eye.2015.87 C4565952!4565952!26021870     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 278.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 278.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26021870.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Eye+(Lond) 2015 ; 29 (9): 1152-5 Nephropedia Template TP {{tp|p=26021870|t=2015. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results |pdf=|usr=}}{{26021870}} gab.com Text Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results JO: Eye (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=26021870 #FOAvip Purpose:: To evaluate frequency of injections, visual and anatomical outcomes of neovascular age-related macular degeneration (nAMD) patients transitioned to intravitreal aflibercept after failure to extend treatment interval beyond 8 weeks with prior intravitreal bevacizumab or ranibizumab. Methods:: Retrospective review of patients with nAMD switched to aflibercept following ?6 prior intravitreal ranibizumab or bevacizumab injections at 4?8-week intervals. Three monthly aflibercept injections were given followed by a treat-and-extend dosing regimen. Results:: Twenty-one eyes of 18 patients who had received a mean of 23.8±18.8 (mean±SD; range 6?62) prior ranibizumab or bevacizumab injections were included. Over a mean follow-up of 24 months after the transition, 9.2±2.9 (range 4?21) aflibercept injections were required. Interval between aflibercept injections increased to 57.3 days (range 35?133 days), as compared with 37±6.1 days (range 29?54 days) with the prior agents (P=0.01). Mean best-corrected visual acuity was preserved (0.42±0.31 vs 0.42±0.23 logMAR; P=0.2). Mean OCT central subfoveal thickness (292.1±83.2??m to 283.6±78.6??m; P=0.4) and mean macular volume (7.9±0.95?mm3 to 7.67±0.94?mm3; P=0.16) remained stable. Conclusion:: Patients requiring treatment more frequently than every 8 weeks with ranibizumab and bevacizumab were transitioned to >8-week treatment interval with aflibercept while maintaining the anatomic and visual gains. Twit Text FOAVip Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results ????Eye (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=26021870 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26021870 #FOAvip English Wikipedia <ref>{{Cite pmid|26021870}}</ref> Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results #MMPMID26021870 Homer N; Grewal DS; Mirza RG; Lyon AT; Gill MK Eye (Lond) 2015[Sep]; 29 (9): 1152-5 PMID26021870show ga Purpose:: To evaluate frequency of injections, visual and anatomical outcomes of neovascular age-related macular degeneration (nAMD) patients transitioned to intravitreal aflibercept after failure to extend treatment interval beyond 8 weeks with prior intravitreal bevacizumab or ranibizumab. Methods:: Retrospective review of patients with nAMD switched to aflibercept following ?6 prior intravitreal ranibizumab or bevacizumab injections at 4?8-week intervals. Three monthly aflibercept injections were given followed by a treat-and-extend dosing regimen. Results:: Twenty-one eyes of 18 patients who had received a mean of 23.8±18.8 (mean±SD; range 6?62) prior ranibizumab or bevacizumab injections were included. Over a mean follow-up of 24 months after the transition, 9.2±2.9 (range 4?21) aflibercept injections were required. Interval between aflibercept injections increased to 57.3 days (range 35?133 days), as compared with 37±6.1 days (range 29?54 days) with the prior agents (P=0.01). Mean best-corrected visual acuity was preserved (0.42±0.31 vs 0.42±0.23 logMAR; P=0.2). Mean OCT central subfoveal thickness (292.1±83.2??m to 283.6±78.6??m; P=0.4) and mean macular volume (7.9±0.95?mm3 to 7.67±0.94?mm3; P=0.16) remained stable. Conclusion:: Patients requiring treatment more frequently than every 8 weeks with ranibizumab and bevacizumab were transitioned to >8-week treatment interval with aflibercept while maintaining the anatomic and visual gains. äTransitioning to intravitreal aflibercept following a previous treat-a(epmc).pdf DeepDyve Pubget Overpricing